Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of DemeRx.

    Client Virtual Booth

    DEMERX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    DemeRx
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Life Science and Technology Park, 1951 NW 7th Ave, Suite 300, Miami Fl 33136
    Telephone
    Telephone
    (786) 347-3500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://demerx.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

    Details:

    A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start enrolment for a Phase I/IIa trial of ibogaine HCl (DMX-1002) in the treatment of opioid use disorder (OUD).


    Lead Product(s): Ibogaine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: DMX-1002

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

    Details:

    The investment aims at developing treatment protocol for safety of patients who are taking ibogaine for treatment of opioid use disorder (OUD).


    Lead Product(s): Ibogaine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: ATAI Life Sciences

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Investment January 24, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search